Pre-market data show Apartment Investment and Management Company (NYSE:AIV) is -6.55% lower at $4.71 after reporting that it has completed separation of Apartment Income REIT Corp. It recently closed at $5.04, fluctuating in a day’s range from $4.88 to $6.48. Scotiabank has a Sector perform rating on AIV’s shares and set a $41 price target. The stock has a consensus Moderate Buy rating and a 52-week trading range of $24.53 to $55.68.
vTv Therapeutics Inc. (NASDAQ:VTVT) is trading at $2.13 down with -28.28 percent or -0.84 point in pre-market trading today following the announcement of topline results of phase 2 Elevage study of Azeliragon in patients with Mild Alzheimer’s disease and type 2 diabetes. It recently closed at $2.97, fluctuating in a day’s range from $2.90 to $3.43.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Xcel Brands Inc. (NASDAQ:XELB) shares traded over -14.39% lower in pre-market trading on Wednesday. The consensus recommendation for the company is Hold.
Shares of Aerpio Pharmaceuticals Inc. (ARPO) are -2.63% lower in pre-market trading this morning. The firm recently announced statistically significant topline results from Razuprotafib Glaucoma phase 2 trial. BTIG Research issued a Buy recommendation for Aerpio Pharmaceuticals Inc. with a target price of $4.
iQIYI Inc. (NASDAQ:IQ) was moving -7.66% lower in pre-market trading for New Street after declaring proposed offering of convertible senior notes and proposed offering of American depositary shares. Alongside 6 buy ratings, IQ scores an average top analyst price target of $25.01.
Veru Inc. (VERU)’s shares, up 239.27% this year, were -7.5% lower in pre-market trading. The firm lately declared positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The average analyst price target is about $9.00, up about 238.04% over the past three months and 178.51% year to date.
Pre-market data show Pennsylvania Real Estate Investment Trust (NYSE:PEI) is -6.86% lower at $0.95. It last finished at $1.02, fluctuating in a day’s range from $0.99 to $1.0697. Analysts believe the stock will be worth $1.00 within the next 12 to 18 months.
Concord Medical Services Holdings Limited (NYSE:CCM) is trading at $3.55 down with -33.15 percent or -1.76 point in pre-market trading today. It recently closed at $5.31, fluctuating in a day’s range from $1.95 to $5.89.
Verastem Inc. (NASDAQ:VSTM) shares traded over -9.5% lower in pre-market trading on Wednesday after revealing the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). BTIG Research has a Neutral rating on the VSTM stock. The shares have a consensus Moderate Buy rating and a 52-week trading range of $1.08 to $4.67.
Shares of Galapagos NV (NASDAQ:GLPG) are -14.99% lower in pre-market trading this morning after Gilead and Galapagos declared new commercialization and development agreement for Jyseleca® (Filgotinib). Alongside 5 buy ratings, GLPG scores an average top analyst price target of $137.48.
Anchiano Therapeutics Ltd. (NASDAQ:ANCN) was moving -7.99% lower in pre-market trading for Wednesday, December 2020 after the company reporting definitive merger agreement with Chemomab Ltd. Oppenheimer a Perform recommendation for Anchiano Therapeutics Ltd.
ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s shares, lower -3.98% over the week, were -16.06% lower in pre-market trading.